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ABSTRACT 
Rippling muscle disease is caused by mutations in the gene encoding 
caveolin-3, the muscle-specific isoform of the scaffolding protein caveolin, a protein 
involved in the formation of caveolae. In healthy muscle, caveolin-3 is responsible 
for the formation of caveolae, which are highly organized sarcolemmal clusters 
influencing early muscle differentiation, signalling and Ca2+ homeostasis. 
In the present study we examined Ca2+ homeostasis and excitation-
contraction coupling in cultured myotubes derived from two patients with Rippling 
muscle disease with severe reduction in caveolin-3 expression; one patient harboured 
the heterozygous c.84C>A mutation while the other patient harboured a homozygous 
splice site mutation (c.102+ 2T>C) affecting the splice donor site of intron 1 of the 
CAV3 gene. Our results show that cells from control and rippling muscle disease 
patients had similar resting [Ca2+]i and 4-chloro-m-cresol-induced Ca2+ release but 
reduced KCl-induced Ca2+ influx. Detailed analysis of the voltage-dependence of 
Ca2+ transients revealed a significant shift of Ca2+ release activation to higher 
depolarization levels in CAV3 mutated cells. High resolution TIRF 
immunofluorescence analysis supports the hypothesis that loss of caveolin-3 leads to 
microscopic disarrays in the co-localization of the voltage-sensing dihydropyridine 
receptor and the ryanodine receptor, thereby reducing the efficiency of excitation–
contraction coupling. 
 
Key words: caveolin-3, rippling muscle disease, excitation–contraction coupling, 
excitation coupled Ca2+ entry, Ca2+ homeostasis, TIRF microscopy 
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INTRODUCTION 
Rippling muscle disease (RMD; MIM# 606072) is a rare autosomal dominant 
disorder caused by mutations in CAV3 (access # 601253) the gene encoding 
caveolin-3 (CAV3), a caveolin isoform exclusively expressed in skeletal, cardiac and 
smooth muscles (Betz et al., 2001; Woodman et al., 2004). Caveolins are small 22 
kDa transmembrane proteins which homo-oligomerize on the plasma membrane 
giving rise to caveolae, or invaginated structures of 50-100 nm in diameter (for 
recent reviews see Cohen et al., 2004; Hnasko and Lisanti, 2003; Hansen and 
Nichols, 2010). In skeletal muscle numerous proteins including ß-dystroglycan, 
nitric oxide synthase, phosphofructokinase, tubulin, cadherin-M converge within 
sarcolemmal caveolae (Galbiati et al., 2001a; Sotgia et al., 2003; Song et al., 1996; 
Garcia-Cardena et al., 1997; Volonte et al., 2003) while in mature muscle fibres, 
caveolins are also distributed in the subsarcolemmal space on the neck of the T-
tubules, where ion channels, pumps, kinases and signaling molecules collect 
(Kristensen et al., 2008; Murphy et al., 2009; Lamb, 2005; Scriven et al., 2005). 
Besides functioning as a converging molecule, CAV3 is involved in myoblast 
differentiation, survival and cell fusion and its transcription level increases early in 
development during muscle tissue differentiation (Galbiati et al., 2001a; Volonte et 
al., 2003). Experiments on zebrafish have demonstrated that injection of embryos 
with CAV3 antisense morpholinos results in embryos with uncoordinated 
movements probably due to disorganized fused myoblasts, chaotic filament bundles 
of the contractile proteins, dispersed mitochondria and poorly developed T-tubules 
(Nixon et al., 2005).  
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Though their exact physiological role is not clear, the above data indicate that 
caveolin-3 plays an important role in muscle function and mutations in CAV3 have 
indeed been linked to several hereditary myopathies among which are Limb Girdle 
Muscular Dystrophy (LGMD; MIM #607801), Rippling Muscle Disease (RMD; 
MIM #606072), Distal myopathy (DM; MIM# 601253) and HyperCKemia 
(Woodman et al., 2004; Gazzerro et al., 2010 Betz et al., 2001). In some cases, 
mutations in CAV3 have also been associated with cardiomyopathy (Catteruccia et 
al., 2009; Hayashi et al., 2004;Vatta et al., 2006; Calaghan and White, 2006). CAV3 
maps on human chromosome 3p25 and is made up of 2 exons; so far 24 missense 
mutations, 1 bp insertion, 3 bp deletions, a splice site substitution and a genomic 
macro deletion have been reported in patients with caveolinopathies (Abourmousa et 
al., 2008; Woodman et al., 2004). Most mutations are inherited in a dominant way 
and lead to a severe decrease in the expression of all CAV3, since mutated and wild 
type proteins multimerize within the Golgi, where they form a complex which is 
tagged for proteolysis and degraded in the proteosome leading to very low levels of 
expression of caveolin-3 on the sarcolemma (Galbiati et al., 1999; Cohen et al., 
2004;). CAV3 is made up of 151 amino acids, of which the first 55 residues 
constitute the NH2 terminus, residues 56-73 make up the scaffolding domain 
important in homo-oligomerization, residues 76-108 form the transmembrane 
domain which gives rise to a hair loop structure, allowing the COOH- and NH2-
teminus to face the same side of the membrane (Galbiati et al., 2001a; Cohen et al., 
2003). Mutations found in patients are more frequent in the NH2 domain, followed 
by the scaffolding and membrane domains (Abourmousa et al., 2008; Woodman et 
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al., 2004). Interestingly, clinical evidences have demonstrated that the same CAV3 
mutation in different populations and even within the same family, can result in a 
different clinical phenotype, indicating the influence of additional factor(s) in the 
phenotypic outcome of the mutation. 
Recently, Fischer et al. identified a mutation in CAV3 in a large German 
family. This family harboured the c.84C>A heterozygous substitution leading to the 
p.D28E mutation (Fischer et al., 2003). Another German family was subsequently 
identified harbouring an autosomal recessive splice site mutation c.102+ 2T>C in 
intron 1 (Müller et al., 2006); both mutations lead to drastically reduced levels of 
expression of CAV3 in skeletal muscle. The patient harbouring the p.D28E mutation 
had clear signs of rippling muscle disease characterized by percussion-induced rapid 
muscle contraction and muscle mounding, painful muscle cramping, elevated 
creatine kinase levels and hypertrophic calves (Fischer et al., 2003) whereas the 
patient harbouring the splice site mutation had muscle weakness, elevated creatine 
kinase levels, percussion induced muscle mounding and mild myopathic 
degeneration with fibre size variation and increase of connective tissue (Müller et al., 
2003). 
While the precise pathomechanism is still elusive, a number of reports have 
indicated that CAV3 may have a role in Ca2+ homeostasis (Calaghan and White, 
2006; Kamishima et al., 2007; Weiss et al., 2008) and it has been shown that 
expression of mutated caveolin in muscle cells alters the function of the 
dihydropyridine receptor (Couchoux et al., 2007). More recently, it was 
demonstrated that CAV3 interacts directly with the ryanodine receptor (RyR1) 
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sarcoplasmic reticulum Ca2+ release channel (Vassilopoulos et al., 2010). In the 
present report we studied excitation–contraction coupling in human skeletal muscle 
myotubes obtained from the two patients harbouring the above described CAV3 
mutations. Our results show that the myotubes from control or RMD patients have 
similar resting [Ca2+] and ryanodine receptor activated Ca2+ release. Interestingly 
however, cells bearing the mutated CAV3 showed a shift in depolarization–induced 
Ca2+ release and a decreased depolarization-induced Ca2+ influx suggesting that lack 
of caveolin leads to a less efficient excitation–contraction coupling. 
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MATERIALS AND METHODS 
Primary skeletal muscle cultures- were established from fragments of muscle 
biopsies obtained from patients undergoing diagnostic testing, as previously 
described (Ducreux et al., 2004). Cells were cultured on 0.17 mm thick glass 
coverslips in growth medium and induced to differentiate into myotubes by culturing 
them in DMEM plus 4.5 mg/ml glucose, 0.5% BSA, 10 ng/ml EGF, 0.15 mg/ml 
creatine, 5 ng/ml insulin, 200 mM glutamine, 600 ng/ml penicillin G and 
streptomycin, and 7 mM HEPES, pH 7.4 for 7-10 days. 
 Cytoplasmic calcium measurements: coverslip grown myotubes were loaded with 
the fluorescent ratiometric Ca2+ indicator fura-2-AM (final concentration 5 µM) in 
differentiation medium for 30 min at 37°C, after which the coverslips were mounted 
onto a 37°C thermostatically controlled chamber which was continuously perfused 
with Krebs-Ringer medium. On-line measurements were recorded using a 
fluorescent Axiovert S100 TV inverted microscope (Carl Zeiss GmbH, Jena, 
Germany) equipped with a 20x water-immersion FLUAR objective (0.17 NA), 
filters (BP 340/380, FT 425, BP 500/530) and attached to a Hamamatsu multiformat 
CCD camera. Images were acquired at 1 second intervals and the exposure time was 
fixed at 100 msec for both (340 and 380 nm excitation) wavelengths. Changes in 
fluorescence were analyzed using an Openlab imaging system and the average pixel 
value for each cell was measured at excitation wavelengths of 340 and 380 nm as 
previously described (Ducreux et al., 2004). Individual cells were stimulated by 
means of a 12- or 8-way 100 mm diameter quartz micromanifold computer 
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controlled microperfuser (ALA Scientific instruments, Westbury N.Y. U.S.A.), as 
previously described (Ducreux et al., 2004).  
Ca2+ influx by TIRF microscopy: depolarization-induced Ca2+ influx was monitored 
by TIRF microscopy in myotubes loaded with fluo-4-AM. Briefly, glass coverslip 
grown and differentiated human myotubes were mounted on a thermostated 
perfusion chamber, bathed continuously in Krebs-Ringer buffer. Excitation-coupled 
Ca2+ entry (ECCE) (Cherednichenko et al., 2004; Bannister et al., 2008) was 
measured after application of 60 mM KCl to myotubes pre-treated with 100 µM 
ryanodine to block RyR1-mediated Ca2+ release. On-line fluorescence images were 
acquired using an inverted Nikon TE2000 TIRF microscope equipped with an oil 
immersion CFI Plan Apochromat 60x TIRF objective (1.49 N.A.) and an electron 
multiplier Hamamatsu CCD camera C9100-13 which allows fast data acquisition as 
previously described (Treves et al., 2010). Our TIRF microscope is equipped with a 
surface reflective interference contrast (SRIC) cube in order to identify the focal 
plane corresponding to the coverglass/cell membrane contact prior to TIRF 
acquisition. The focus was maintained at the coverglass/cell membrane contact by 
using the perfect focus system (PFS) that exploits an infrared laser beam and a 
quadrant diode for the online control of the microscope’s focusing motor. Fluo-4 
loaded cells were excited with a solid-state laser beam at 488 nm and the emitted 
fluorescence was collected through a 520 narrow band filter. Data were analysed 
using Metamorph imaging software (Molecular Devices). 
Electrophysiological measurements and confocal Ca2+ imaging: human myoblasts 
were grown on laminin-coated glass coverslips and differentiated into myotubes. 
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Cells were voltage-clamped in the whole-cell patch clamp configuration with low 
resistance borosilicate glass micropipettes (1-3 MΩ) using an Axopatch 200B 
amplifier (Axon Instruments) controlled by a custom-written data-acquisition 
software developed by LabView (National Instruments). The pipette solution 
contained (in mM) 100 CsAsp, 20 tetraethylammonium(TEA)-Cl, 10 HEPES, 5 
MgCl2, 5 Na2ATP, 0.05 EGTA, 0.1 K5-Fluo-3 at pH 7.2 (adjusted with CsOH). 
External solution contained (in mM) 130 CsCH3SO3, 2 MgCl2, 2 CaCl2, 10 Glucose, 
20 HEPES at pH 7.4 (adjusted with CsOH). The voltage protocol consisted of 
stepwise depolarizations (50 ms) from a holding potential of –80 mV to increasing 
potentials from –60 mV to +10 mV. Activation of the voltage-dependent 
dihydropyridine receptor (skeletal DHPR CaV1.1) triggered Ca2+ release from the SR 
via electro-mechanical coupling between DHPR and RyR1. Changes in [Ca2+]i were 
simultaneously recorded with membrane currents using the fluorescent Ca2+ 
indicator K5-Fluo-3 (Biotium) and a laser-scanning confocal microscope 
(MicroRadiance, BioRad) with a 60x water immersion objective lens. Fluo-3 was 
excited at 488 nm with an argon ion laser, and emitted light was collected above 500 
nm. Linescan images were recorded at a rate of 500 lines/s. Confocal images were 
analyzed in ImageSXM (free software based on NIH Image (Barrett, 2002)) and 
further processed together with the voltage clamp data using IgorPro (Wavemetrics). 
Changes in [Ca2+]i are expressed as changes in fluorescence (ΔF/F0). All 
measurements have been performed at room temperature. 
Western blotting: total muscle homogenate and SR fraction obtained from skeletal 
muscle leftover fragments which had been stored in liquid N2, were isolated. 
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Proteins were separated by SDS PAGE, blotted onto nitrocellulose and probed with 
antibodies against caveolin-3 (GeneTex Inc., catalog N° GTX109650), RyR1 
(Thermo Scientific, catalogue N° MA3-925), α1.1 subunit of the DHPR  (Santa Cruz 
sc- 8160), SERCA2 (Santa Cruz sc-8095), calsequestrin (Delbono et al., 2007) and 
glycogen phosphorylase (Santa Cruz sc-4634) followed by peroxidase conjugated 
secondary antibodies. Bands were visualized by chemiluminescence, using the Super 
Signal West Dura kit from Thermo Scientific. For comparison, the intensities of the 
immunoreactive bands were quantified by densitometry using Bio-Rad GelDoc 
2000; intensities were corrected for glycogen phosphorylase (total muscle 
homogenate) and calsequestrin (total SR). 
Immunofluorescence analysis: glass coverslip grown and differentiated myotubes 
were fixed in an ice-cold solution of acetone:methanol (1:1) for 20 min, rinsed 2 
times with phosphate buffer saline (PBS) and blocked with 10% blocking buffer 
(Roche Applied Science) for 60 min at room temperature. Coverslips were incubated 
with goat anti- α1.1 subunit of the DHPR  (final concentration 10µg/ml) and mouse 
anti–RyR (final concentration 10µg/ml) in PBS; after 60 min coverslips were rinsed 
3 times 5 min each with PBS and incubated with donkey- anti-goat FITC (Santa 
Cruz) for 60 minutes, extensively washed with PBS and incubated with Alexa 
Fluor405 conjugated goat-anti mouse IgG (Invitrogen). After 60 minutes coverslips 
were washed and mounted in glycerol mounting medium. Fluorescence was 
visualized through a 100x oil immersion CFI Plan Apochromat TIRF objective (1.49 
NA), by exciting at 488 (Sapphire laser) to visualize FITC, and at 405 nm using a 
laser from Coherent laboratories (Coherent labs Inc). AlexaFluor 405 fluorescence 
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was visualized using a BrightLine CH 427 filter (AHF Analysentechnir AG, 
Tubingen, Germany). Co-localization analysis of α.11DHPR and RyR was 
performed using the co-localization application included in the Metamorph 5.7.4 
software package as previously described (Treves et al., 2010); only myotubes with 
>2 nuclei were analysed. 
Statistical analysis: Statistical analysis was performed using the Student’s t test for 
paired samples; means were considered statistically significant when the P value was 
<0.05. The Origin computer program (Microcal Software, Inc., Northampton, MA, 
USA) was used for statistical analysis. 
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RESULTS  
 The aim of the present report is to assess whether mutations in CAV3 lead to 
dysregulation of Ca2+ homeostasis in human muscle cells. In order to assess this we 
first monitored whether the absence/reduced levels of CAV3 affects the expression 
levels of the main components of the excitation-contraction (E-C) coupling 
machinery, namely the dihydropyridine receptor (DHPR) and the ryanodine receptor 
(RyR) calcium channels, calsequestrin and the SERCA Ca2+ pump (Treves et al., 
2009). Figure 1 A shows Western blot analysis of total muscle homogenate (CAV3, 
RyR1, DHPR,) and of the total sarcoplasmic reticulum (SR) fraction (SERCA2, 
calsequestrin) obtained from muscle biopsy fragments of the patients harbouring 
CAV3 mutations and controls. As shown previously (Fischer et al., 2003; Müller et 
al., 2006), the amount of CAV3 present in the muscle homogenate of both patients is 
greatly reduced. Interestingly, no significant differences were found in the amounts 
of RyR1, DHPR α1.1, SERCA2 and calsequestrin expressed in the muscle biopsy 
from these patient compared to that expressed in control biopsies. Thus, the absence 
of caveolin-3 does not grossly alter the expression level of the protein components 
involved in Ca2+ homeostasis.  
 We next studied the Ca2+ homeostasis of the myotubes from the two patients 
with RMD. Though myotubes were obtained from the two patients with different 
mutations, as shown in figure 1A and reported for other CAV3 mutations 
(Aboumousa et al., 2008; Woodman et al., 2004), both the c.84C>A and 
c.102+2T>C substitutions resulted in a drastic reduction of CAV3 expression. 
Because of this and since western blot analysis revealed similar levels of expression 
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of the main protein components involved in E-C coupling (figure 1), we pooled the 
results obtained on Ca2+ homeostasis on the myotubes from the two patients. Figure 
2 shows that the mean resting fluorescent ratio and the peak Ca2+ release obtained by 
stimulating the cells with maximal amounts of either KCl (mimicking electrical 
depolarization) or 4-chloro-m-cresol (which directly activates the RyR1)(Zorzato et 
al., 1993) were not significantly different between control myotubes and myotubes 
from the two patients with RMD when the experiments were performed in Krebs 
Ringer +100 µM La3+, a general Ca2+ channel blocker used to prevent any 
contaminating Ca2+ influx. Panel C shows representative traces of Ca2+ release 
experiments performed in the presence of contaminating Ca2+ plus 100 µM La3+. 
These results indicate that the lack of CAV3 does not grossly affect RyR1 mediated 
Ca2+ release from the intracellular stores.  
  A more detailed investigation of the electro-mechanical coupling in control 
and RMD myotubes however, revealed significant differences in the voltage-
dependent Ca2+ release properties of cells from RMD patients. Using an 
electrophysiological approach combined with confocal Ca2+ imaging we studied 
Ca2+ release induced by membrane depolarization. Figure 3 panel A shows original 
paired sample traces for current (lower trace) and Ca2+ transient (upper trace) in 
control human myotubes at increasing levels of membrane depolarization (for 
representative current traces see Supp. Figure S1). As expected, increasing 
depolarization results in an increase in Ca2+ release, which saturates as the 
depolarizing voltage pulse reaches –10 mV. Panel B shows the line profiles and 
corresponding linescan images of the Ca2+ response to a depolarizing step from –80 
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to–20 mV in control (upper black trace) and RMD myotubes (lower red trace), 
respectively.  At the same trigger potential, RMD myotubes present lower voltage-
induced Ca2+ release amplitudes from the SR when compared with control cells. The 
voltage-dependence of Ca2+ release is summarized in panel C; normalized peak Ca2+ 
release amplitudes are plotted as a function of the test potential. The membrane 
potentials at half maximal Ca2+ release (V1/2) are indicated revealing a significant 
shift (P< 0.05) in V1/2 from -29.4±1.8 mV in control myotubes to –24.7±3.2 in RMD 
myotubes. This right-shift in V1/2 is further accompanied by a shift in the maximal 
Ca2+ transient amplitude from –10 mV in control to 0 mV in RMD myotubes. These 
results indicate that depletion of CAV3 reduces the coupling efficiency between the 
DHPR and the RyR.  
 Recently it was shown that in skeletal muscle myotubes, plasma membrane 
depolarization is accompanied by Ca2+ influx, which is mediated by the DHPR and 
has been defined as excitation coupled Ca2+ entry (ECCE) (Cherednichenko et al., 
2004; Bannister et al., 2009). Though the functional significance of this Ca2+ influx 
is currently unknown, it depends on the presence of both the RyR1 and DHPR. Since 
(i) depolarization-induced Ca2+ release is affected by the loss CAV3 (figure 3 and 
Couchoux et al., 2007), (ii) studies by Vassilopoulos et al. (2010) demonstrated a 
direct interaction between CAV3 and the RyR1 and (iii) ECCE depends on the 
presence of the DHPR and of the RyR, we studied ECCE in the myotubes from the 
two RMD patients. Figure 4 summarizes the pooled results obtained by TIRF 
microscopy on Ca2+ influx activated by 60 mM KCl. As indicated in the Methods 
section, myotubes were pre-treated with 100 µM ryanodine in order to block Ca2+ 
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release from the SR via RyR1 (Meissner, 1986). The bottom trace in figure 4B (.-.-.-
) and the inset in figure 4 C show that in the absence of extracellular Ca2+  (and in the 
presence of 100 µM La3+ ) the addition of 60 mM KCl does not lead to a change in 
fluo-4 fluorescence, confirming that the increase in Fluo-4 is not due to calcium 
release from the SR. When the experiments were conducted in the presence of 2 mM 
Ca2+, on the other hand, the addition of KCl was accompanied by a transient increase 
in Fluo-4 fluorescence confirming that this fluorescence increase represents Ca2+ 
influx from the extracellular medium. We then compared the extent of the KCl-
activated Ca2+ influx in myotubes from the two RMD patients to that observed in 
myotubes from  controls. The traces in figure 4 B and bar graph plots in figure 4C 
show that myotubes from the RMD patients have a significantly smaller (two-fold) 
Ca2+ influx peak compared to that obtained in control myotubes.  
 Since the lack of CAV3 is not accompanied by gross alterations in the 
expression levels of the RyR and DHPRs, the above results indicate that the lack of 
this protein may affect the topographical distribution of these two Ca2+ channels on 
their respective membranes. In order to verify this, we performed 
immunofluorescence analysis of the distribution of the DHPR and RyR in TIRF 
mode. Figure 5 shows a representative photomicrograph of a myotube from a control 
individual observed with a SRIC filter to show that the selected focal plane is at the 
glass coverslip/ membrane interface (left). This focal plane was fixed through the 
perfect focus system and imunofluorescence analysis was subsequently performed. 
The central left and right panels of figure 5 show the punctuated fluorescent 
distribution of the DHPRα1.1 and RyR on or within 100 nm of the plasma 
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membrane and the panel on the right shows the merged images revealing areas of co-
localization (arrows). Table 1 shows the results of detailed co-localization analysis 
(n=10 cells): the lack of CAV3 caused a 30% reduction in the area of overlap 
between the RyR and the DHPR; this was due to a relative increase in the 
distribution of RyRs in areas not containing DHPRs   
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DISCUSSION 
In the present study we investigated whether severe reduction of CAV3 as 
seen in two patients with RMD affects E-C coupling, the physiological process 
whereby an electrical signal, the depolarization of the muscle fibre, is converted into 
a chemical signal, i.e. release of Ca2+ from the sarcoplasmic reticulum, leading to 
muscle contraction and force development (Fleischer and Inui, 1989; Rios and 
Pizarro, 1991). This process depends on the fine micro architecture underlying the 
calcium release unit whereby the voltage sensing DHPR present on T-tubules faces 
ordered arrays of RyR1 on the SR junctional membrane (Franzini-Armstrong and 
Jorgensen, 1994). Mutations in genes encoding several proteins involved in E-C 
coupling and Ca2+ homeostasis have been shown to be linked to neuromuscular 
disorders such as Central core disease, Multimini core disease, Centronuclear 
myopathy, King Denborough syndrome and Malignant Hyperthermia (Treves et al., 
2005; Wilmhurst et al., 2010; Zhou et al., 2007). We obtained myotubes from one 
patient with a homozygous splice site mutation leading to very low levels of 
caveolin-3 wild type transcript (Müller et al., 2006). The other patient harbored the 
heterozygous p.D28E substitution and also expressed very low levels of caveolin-3; 
though substitution of an aspartic acid residue for a glutamic acid residue may seem 
of minor consequence since the two amino acids are negatively charged, 
mutagenesis studies on other proteins have indicated that such substitutions can lead 
to protein instability by causing structural perturbations (Mizrahi et al., 1994). Thus, 
though the patients harbored different substitutions and had different clinical 
symptoms, both exhibited a severe reduction in the amount of CAV3 expressed. 
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Thus by pooling the functional data obtained on myotubes from the two patients, we 
studied the effect of CAV3 depletion, irrespective of the compensatory mechanisms 
activated by the patient. The results on cytoplasmic Ca2+ homeostasis reveal that the 
absence of CAV3 does not cause significant alterations of E-C coupling in myotubes 
and are in agreement with those obtained by Weiss et al. (2008) who showed that 
loss of caveolin does not affect either the resting [Ca2+] or depolarization-induced 
peak Ca2+ release in mouse skeletal muscle cells. A deeper investigation into the 
electro-mechanical coupling of caveolin-3 depleted cells however, revealed a 5 mV 
shift in the V1/2 activating potential, resulting in reduced Ca2+ release at low 
depolarizing potentials. Though different from what was reported in mouse skeletal 
muscle (Weiss et al., 2008), these results support the findings of Calaghan et al. 
(2006) on rat ventricular myocytes treated with methyl-ß-cyclodextrin to disrupt 
caveolae. In the latter cell type removal of CAV3 resulted in a reduced SR fractional 
Ca2+ release indicating a loss in E-C coupling efficiency. Thus, as recently suggested 
by Dart, lipid microdomains may be involved in the fine regulation of ion channels 
and alterations in the properties and composition of the lipids or alterations in the 
distribution of caveolins may affect channel gating kinetics, trafficking and surface 
expression of proteins (Dart, 2010). 
We were interested in investigating whether the reduced E-C coupling 
efficiency in CAV3 mutated cells might have downstream effects. In fact, in a recent 
study Murata et al. (2007) showed that caveolin-1 is essential for Ca2+ entry in 
endothelial cells; upon stimulation with acetylcholine endothelial cells from 
caveolin-1 KO mice have a “normal” peak Ca2+ transient but a 50% reduction in 
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agonist invoked Ca2+ entry. In skeletal muscle cells, E-C coupling is thought to be 
essentially independent of extracellular Ca2+. However, a number of recent studies 
have revealed that activation of the DHPR Ca2+ channel is accompanied by influx of 
Ca2+ (Cherednichenko et al., 2004; Bannister et al., 2008), especially during long 
depolarization. This phenomenon requires the physical presence of the DHPR and 
RyR1 and is enhanced in cells bearing RyR1 mutations linked to Malignant 
Hyperthermia (Cherednichenko et al., 2008; Yang et al., 2007). We found that 
muscle cells from RMD patients had a 50% reduction in KCl induced Ca2+ influx. 
Western blot analysis revealed no significant differences in the level of expression of 
DHPR or RyR1, thus the reduced ECCE is apparently not due to lack of the proteins 
responsible for the Ca2+ influx. One possibility that would explain how the lack of 
CAV3 decreases ECCE is that lack of CAV3 affects the distribution of the DHPR 
and RyR1 on their respective membranes. A hypothesis supported by the co-
localization experiments performed in TIRF mode as well as by recent results by 
Vassillopoulos et al. (2010) who showed that RyR1 and caveolin-3 co-
immunoprecipitate and that caveolin-3 interacts directly with a transmembrane 
domain of the RyR1. Thus the lack of CAV3 seems to derange the micro-
architecture of the main protein components of the E-C coupling machinery leading 
(i) to a less efficient coupling, particularly evident at low depolarizing stimuli and 
(ii) to a decrease in ECCE. We are aware that the TIRF experiments were performed 
on myotubes and theoretically the co-localization results could reflect a different 
degree of differentiation of cells from control and RMD patients. In order to 
minimalize this possibility, we only analyzed those myotubes containing >2 nuclei. 
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In support of our finding, it was demonstrated that skeletal muscles from CAV3 KO 
mice show abnormalities in the organization of the T-tubules with dilated and 
longitudinally oriented T-tubules (Galbiati et al., 2001).  
Though the results of the present investigation do not explain how the 
rippling phenomena are induced by passive stretching and percussion, the finding of 
reduced E-C coupling efficiency and reduced Ca2+ influx may explain, at least in 
part, the phenotypic characteristics of patients with reduced CAV3 levels. 
Interestingly, Lamb (2005) suggested that the induction of rippling movements may 
be caused by stretch induced silent action potentials occurring within the T-tubules 
of skeletal muscle fibers. Though possible, it is experimentally very difficult to 
prove whether action potentials can escape from T-tubules since cultured myotubes 
do not differentiate sufficiently in vitro. 
 In conclusion, we show that loss of caveolin-3 leads to a decrease in the E-C 
coupling efficiency in human myotubes and this feature may be one of the 
underlying causes of the rippling phenotype seen in patients harboring CAV3 
mutations. 
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FIGURE LEGENDS 
Figure 1: Western blot analysis of skeletal muscle proteins in muscle biopsies 
from the two RMD patients harboring CAV3 mutations. Proteins (30 µg) in the 
total muscle homogenate (CAV3, α1.1 DHPR, RyR1 and glycogen phosphorylase) 
or total SR fraction (20 µg) (SERCA2 and calsequestrin) were blotted onto 
nitrocellulose and probed with the indicated antibodies as specified in the Methods 
section. The relative expression levels of the immunopositive bands in the biopsy 
from the RMD patient harboring the c.84C>A mutation (left) and the homozygous 
splice site mutation c.102+ 2T>C (right) were compared to that of control biopsies 
which were considered 100%; intensity values were estimated by densitometric 
analysis of the indicated number of blots and normalized with respect to the band 
intensity of glycogen phosphorylase (total homogenate) or calsequestrin (SR). Bars 
represent mean±S.E.M of n experiments; * P< 0.0001. 
Figure 2: Characterization of “global” Ca2+ homeostasis in myotubes with 
CAV3 deficiency. Calcium imaging was performed in fura-2 loaded myotubes as 
described in the Methods section. A. Mean (±S.E.M. of n= 58 and 92 for control and 
RMD, respectively) resting [Ca2+] (expressed as fluorescence intensity ratio 340/380 
nm) was not different in control and RMD myotubes. B. Mean (±S.E.M.) peak Ca2+ 
increase induced by the addition of 100 mM KCl (inducing depolarization) and 600 
µM 4-chloro-m-cresol (4-cmc, RyR1 agonist) in the presence of Krebs-Ringer 
medium (KR) containing 100 µM La3+. Open boxes, control myotubes; grey boxes, 
myotubes from Cav-3 deficient myotubes  (n= 7- 15 measurements) C. Traces 
showing fura-2 change in fluorescence (ratio 340/380 nm) of individual myotubes 
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from a control and a CAV3 mutation-bearing patient in response to 100 mM KCl and 
600 µM 4-cmc. 
Figure 3: Voltage-dependence of Ca2+ transients in control and RMD myotubes. 
Cells were patch-clamped and held at a holding potential (VH) of –80 mV. A. Paired 
sample traces of current (lower trace) and Ca2+ release recordings (upper trace) at 
different test potentials (from –40 to 0 mV) in a fluo-3 loaded control myotube. 50-
ms depolarizations to increasing membrane potentials activated Ca2+ release from 
the SR. B. Comparison of Ca2+ release during a depolarizing step to –20 mV in 
control (black) and Cav-3 deficient RMD (red) myotubes. Linescan images and line 
profiles show the reduced Ca2+ transient amplitude in caveolin-3 deficient RMD 
myotubes at same trigger voltage when compared with control. C. Summary of the 
voltage-dependence of Ca2+ release in control (WT, n=10) and caveolin-3 deficient 
RMD myotubes (n=8). Ca2+ transient amplitudes have been normalized to the 
maximal release amplitude in each cell. Membrane potentials at half-maximal 
activation (V1/2) indicate a right-shift of the voltage-dependence in RMD myotubes 
(P<0.05). 
Figure 4: TIRF measurements of Ca2+ influx induced by 60 mM KCl in human 
myotubes. A.  Myotubes from a control patient were visualized by brightfield (top 
left panel), with a surface reflection interference contrast (SRIC) filter to visualize 
and fix the focal plane of the coverglass/cell membrane interphase (top central 
panel). Next panels show pseudocolored ratiometric images (peak fluorescence after 
addition of KCl/ resting fluorescence) of fluo-4 fluorescence changes at the indicated 
time-points after application of KCl. Fluorescence was monitored through a 60x 
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TIRF objective and analysed using Metamorph as detailed in the Methods section. 
Bar indicates 30 µm. B. Representative traces from ECCE showing changes in fluo-4 
fluorescence in a myotube from a control individual (_____) and a patient 
harbouring a CAV3 mutation (…….) stimulated with 60 mM KCl in the presence of 
2 mM Ca2+ or myotubes from a control in the absence of added Ca2+ and in the 
presence of 100 µM La3+ (.-.-.-.-.). TIRF measurements were performed as indicated 
in the Methods section in myotubes pretreated with 100 µM ryanodine. C. Bar graph 
depicting mean (±S.E.M.) peak increase of fluo-4 fluorescence induced by 60 mM 
KCl in control and caveolin-3 deficient myotubes in the presence of 2 mM Ca2+. 
Insert shows the mean (±S.E.M.) peak fluo-4 fluorescence increase of control 
myotubes in the presence of 100 µM La3+ (grey bar) or 2 mM Ca2+ (empty bar).  
Figure 5: Co-immunolocalization of the α1.1 subunit DHPR and RyR1 by TIRF 
immunofluorescence in human myotubes from a control individual. Myotubes 
were visualized using an inverted Nikon TE2000 TIRF microscope equipped with a 
CFI Plan Apochromat 100x TIRF objective (1.49 NA). Left panel shows 
photomicrograph of cells through a SRIC filter; central left panel shows the same 
cells excited with a Sapphire laser at 488 nm (α1.1 subunit of the DHPR; green 
fluorescence); central right panel shows photomicrograph of the same cells excited 
at 405 and visualized through a BrightLine CH 427 filter (RyR; dark blue 
fluorescence). Right panel, merged images using the “colour-combine” option 
included in the Metamorph software package. Arrows indicate overlapping pixels 
(light blue). Bar indicates 10 µm. 
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